What do systematic reviews say?

2,543 questions · 2,589 findings · 168 reviews · Schizophrenia

Sort:Best matchNewestHighest certainty Download CSV

No studies found 601 · 23.2%GRADE not reported 446 · 17.2%Very low 721 · 27.8%Low 505 · 19.5%Moderate 274 · 10.6%High 42 · 1.6%

H2 receptor antagonists vs placebo

Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

H2 receptor antagonists vs placebo

Change in BMI · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 79 participants
Very low

H2 receptor antagonists vs placebo

Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain

H2 antagonists showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
RR 1.07 [0.72, 1.57]
2 studies · 189 participants
Low

H2 receptor antagonists vs placebo

Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

H2 receptor antagonists vs placebo

Nausea · people with schizophrenia with antipsychotic‐induced weight gain

H2 antagonists showed no clear difference in reports of nausea compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
RR 1.13 [0.34, 3.68]
1 study · 175 participants
Low

Monoamine modulators vs placebo

Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Monoamine modulators vs placebo

Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 103 participants
Low

Monoamine modulators vs placebo

Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Monoamine modulators vs placebo

Change in BMI · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 103 participants
Low

Monoamine modulators vs placebo

Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain

Monoamine modulators showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
RR 1.05 [0.56, 1.94]
3 studies · 115 participants
Low

Metformin vs placebo or no treatment

Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 131 participants
Low

Monoamine modulators vs placebo

Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Monoamine modulators vs placebo

Nausea · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Topiramate vs placebo or no treatment

Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Topiramate vs placebo or no treatment

Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 168 participants
Very low

Topiramate vs placebo or no treatment

Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Topiramate vs placebo or no treatment

Change in BMI · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 120 participants
Very low

Topiramate vs placebo or no treatment

Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain

Topiramate showed no clear difference in leaving the study early: for any reason compared with placebo or no treatment (low certainty).

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
RR 1.09 [0.85, 1.41]
2 studies · 132 participants
Low

Topiramate vs placebo or no treatment

Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Topiramate vs placebo or no treatment

Nausea · people with schizophrenia with antipsychotic‐induced weight gain

Topiramate showed no clear difference in reports of nausea compared with placebo or no treatment (low certainty).

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
RR 1.2 [0.26, 5.44]
2 studies · 120 participants
Low